Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars®. She has been working on AJMC since 2014 and has been with AJMC’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
AJMC's Dr Fendrick Testifies on Benefit of Clinical Nuance
A. Mark Fendrick, MD, co-editor-in-chief of The American Journal of Managed Care and director of the University of Michigan Center for Value-Based Insurance Design, testified before a Michigan senate subcommittee on the benefit of clinical nuance.
What It Means to Be a Physician Leader: A Q&A With Dr Anthony Slonim
For the second year, Anthony D. Slonim, MD, DrPH, is in the running for Modern Healthcare’s 50 Most Influential Physician Executives and Leaders. Recently, he discussed what it means to be a physician leader, the industry’s move to population health, and more.
Bernie Sanders Releases Broad Outline of Single-Payer Healthcare Plan
Just hours before Bernie Sanders (I-VT) took the stage to face off against Hillary Clinton for the last Democratic presidential debate before the Iowa caucus, the senator released an outline of his single-payer healthcare plan.
Insured and Uninsured Alike Report Difficulty Paying Medical Bills
While the prevalence of problems paying medical bills may be greater in certain groups compared with others, almost anyone can experience difficulty paying medical bills, according to the results of a survey from Kaiser Family Foundation/New York Times.
Dr Joshua Cohen Considers the Cons of Bundled Payments
Bundled payments may be part of the future in healthcare’s move to value-based care, but this payment scheme runs into the challenge of penalizing providers for factors that are beyond their control, explained Joshua T. Cohen, PhD, research associate professor of medicine at Tufts Medical Center.
Rivaroxaban Safe and Effective in Cancer Patients With Thrombosis
Although rivaroxaban was approved by the FDA in 2012, there has remained a knowledge gap about how it works with cancer patients. A recent study found that the therapy is safe and effective when used among patients with cancer.